Biorem Inc Stock Current Liabilities
BRM Stock | CAD 3.01 0.02 0.67% |
BioRem Inc fundamentals help investors to digest information that contributes to BioRem's financial success or failures. It also enables traders to predict the movement of BioRem Stock. The fundamental analysis module provides a way to measure BioRem's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BioRem stock.
Total Current Liabilities is likely to drop to about 7.9 M in 2024. Non Current Liabilities Total is likely to drop to about 1.8 M in 2024. BioRem | Current Liabilities |
BioRem Inc Company Current Liabilities Analysis
BioRem's Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
BioRem Current Liabilities Driver Correlations
Understanding the fundamental principles of building solid financial models for BioRem is extremely important. It helps to project a fair market value of BioRem Stock properly, considering its historical fundamentals such as Current Liabilities. Since BioRem's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of BioRem's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of BioRem's interrelated accounts and indicators.
Click cells to compare fundamentals
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
Competition |
BioRem Total Current Liabilities
Total Current Liabilities |
|
In accordance with the recently published financial statements, BioRem Inc has a Current Liabilities of 0.0. This is 100.0% lower than that of the Machinery sector and 100.0% lower than that of the Industrials industry. The current liabilities for all Canada stocks is 100.0% higher than that of the company.
BioRem Current Valuation Drivers
We derive many important indicators used in calculating different scores of BioRem from analyzing BioRem's financial statements. These drivers represent accounts that assess BioRem's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of BioRem's important valuation drivers and their relationship over time.
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Market Cap | 15.5M | 20.9M | 32.3M | 13.6M | 12.3M | 9.6M | |
Enterprise Value | 9.1M | 12.8M | 33.5M | 14.6M | 13.1M | 9.0M |
BioRem Fundamentals
Return On Equity | 0.6 | ||||
Return On Asset | 0.15 | ||||
Profit Margin | 0.11 % | ||||
Operating Margin | 0.07 % | ||||
Current Valuation | 39.9 M | ||||
Shares Outstanding | 15.8 M | ||||
Shares Owned By Insiders | 1.90 % | ||||
Shares Owned By Institutions | 0.44 % | ||||
Number Of Shares Shorted | 2.67 K | ||||
Price To Earning | 3.01 X | ||||
Price To Book | 4.36 X | ||||
Price To Sales | 1.53 X | ||||
Revenue | 25.17 M | ||||
Gross Profit | 6.24 M | ||||
EBITDA | 3.47 M | ||||
Net Income | 2.18 M | ||||
Cash And Equivalents | 5.75 M | ||||
Cash Per Share | 0.16 X | ||||
Total Debt | 4.19 M | ||||
Debt To Equity | 1.05 % | ||||
Current Ratio | 2.24 X | ||||
Book Value Per Share | 0.43 X | ||||
Cash Flow From Operations | 490.03 K | ||||
Short Ratio | 0.21 X | ||||
Earnings Per Share | 0.29 X | ||||
Beta | 0.85 | ||||
Market Capitalization | 46.45 M | ||||
Total Asset | 24.08 M | ||||
Retained Earnings | (1.92 M) | ||||
Working Capital | 6.71 M | ||||
Net Asset | 24.08 M |
About BioRem Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BioRem Inc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioRem using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioRem Inc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for BioRem Stock Analysis
When running BioRem's price analysis, check to measure BioRem's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioRem is operating at the current time. Most of BioRem's value examination focuses on studying past and present price action to predict the probability of BioRem's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioRem's price. Additionally, you may evaluate how the addition of BioRem to your portfolios can decrease your overall portfolio volatility.